Company profile

Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ (DBI) AG is a listed biotechnology company based in Hennigsdorf near Berlin that holds shares in different biotech enterprises.

DBI shares (DE000A0Z25L1) are traded on the open market of Dusseldorf Stock Exchange.

DBI was originally founded as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014.

Management & Network

Founders and Executive Board members of DBI are Dr. Bernd Wegener (Chief Executive Officer) and Dr. Andreas Bergmann (Chief Scientific Officer).

The Supervisory Board of DBI comprises Renke Lührs (Chairman), Dr. Metod Miklus (Vice Chairman) and Dr. Ute Kilger.

DBI is part of a comprehensive international network of leading scientists, institutes and companies, from the fields of biotechnology, pharma, medicine, and life sciences. This enables access to valuable patient’s data, such as blood samples from clinical trials. 


DBI  primarily invests in companies that develop drug candidates with a unique selling point and blockbuster potential.

DBI aims to continuously expand its shareholding portfolio. The portfolio currently comprises four investments:

Adrenomed AG develops the first-in-class monoclonal Adrenomedullin-specific antibody Adrecizumab as a targeted therapy against septic shock to reduce sepsis mortality. Adrecizumab has an excellent toxicology and safety profile and will now be tested in patients with early septic shock (Clinical Phase II).

Oncoprevent GmbH and AngioBiomed GmbH focus on the prevention of breast cancer and inhibition of tumor growth, respectively.

My Life Diagnostics GmbH serves as a think tank for the development of R&D projects.


Shareholding structure

Organigramm der DBI AG

Shareholding Principles

Learn more ...

Adrenomed AG

Adrecizumab | Targeted therapy against septic Shock

Angiobiomed GmbH

AB2302 | Targeted anti-angiogenic tumor therapy